Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06742190 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy
A Phase 3 study of Multifocal Motor Neuropathy (MMN) and MMN, sponsored by argenx.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 115
- Enrollment target
- 20
- Study locations
NCT06742190 is a Phase 3 study of Multifocal Motor Neuropathy (MMN) and MMN that is actively recruiting participants, run by argenx. The registered enrollment target is 115 participants. The trial reports 20 study locations across 13 states.
The verdict
NCT06742190, a Phase 3 study of Multifocal Motor Neuropathy (MMN) and MMN, is actively recruiting participants, sponsored by argenx.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 115 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to compare empasiprubart and IVIg in adult patients with MMN. The study consists of a double-blinded part A (empasiprubart, IVIg) and an open-label part B (empasiprubart). The maximum study duration for participants is up to 49 months. More information can be found here: https://clinicaltrials.argenx.com/empassion
Conditions Studied
Interventions
- BIOLOGICAL Empasiprubart
- BIOLOGICAL IVIG (Intravenous Immunoglobulin)
- OTHER Empasiprubart-placebo
- OTHER IVIg-placebo
Study Locations (20)
Florida
- EZR Research LLC - Boca Raton
- Healthcare Innovations Institute, LLC - Coral Springs
- University of Miami Miller School of Medicine - Miami
- University of South Florida - Tampa
California
- The Neurology Group - Pomona
- Samir Macwan, M.D., Inc. - Rancho Mirage
- University of California San Francisco - San Francisco
Maryland
- Perelman Center for Advanced Medicine - Columbia
- UC Irvine - MDA ALS and Neuromuscular Center - Columbia
New York
- Dent Neurologic Institute Amherst - Amherst
- Columbia University Medical Center - New York
Arizona
- HonorHealth Neurology - Bob Bove Neuroscience Institute - Neurology - Scottsdale
Colorado
- University of Colorado - Anschutz Cancer Pavilion (Neuro Onc Clinic) - Aurora
Connecticut
- Yale University School of Medicine - New Haven
District of Columbia
- Medstar Health Research Institute - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2024-12-18 |
| Est. Completion | 2029-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06742190
The ClinicalTrials.gov registry entry for NCT06742190 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 115 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is argenx, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Multifocal Motor Neuropathy (MMN) appearing as the primary indexed condition, and to 4 interventions - of which Empasiprubart is the first listed.
NCT06742190 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT06742190 about?
NCT06742190 is a clinical study titled "A Study to Assess the Efficacy and Safety of Empasiprubart Versus IVIg in Adults With Multifocal Motor Neuropathy". The main purpose of this study is to compare empasiprubart and IVIg in adult patients with MMN. The study consists of a double-blinded part A (empasiprubart, IVIg) and an open-label part B (empasiprubart). The maximum study duration for participants is up to 49 months. More information can be found...
What is the current status of trial NCT06742190?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 115 participants. The study started on 2024-12-18. Estimated completion is 2029-12.
What conditions does trial NCT06742190 study?
This clinical trial studies the following conditions: Multifocal Motor Neuropathy (MMN), MMN.
What interventions are being tested in trial NCT06742190?
The interventions under investigation include: Empasiprubart (BIOLOGICAL), IVIG (Intravenous Immunoglobulin) (BIOLOGICAL), Empasiprubart-placebo (OTHER), IVIg-placebo (OTHER).
Who is sponsoring clinical trial NCT06742190?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06742190 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multifocal Motor Neuropathy (MMN)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.